• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).

作者信息

Ball Brian J, Arslan Shukaib, Koller Paul, Ngo Dat, Afkhami Michelle, Salhotra Amandeep, Al-Malki Monzr, Aribi Ahmed, Ali Haris, Sandhu Karamjeet, Otoukesh Salman, Amanam Idoroenyi, Pourhassan Hoda, Artz Andrew, Curtin Peter, Stein Anthony, Nakamura Ryotaro, Marcucci Guido, Smith Eileen, Pullarkat Vinod, Aldoss Ibrahim

机构信息

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.

出版信息

Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10.

DOI:10.1080/10428194.2022.2116934
PMID:36089918
Abstract
摘要

相似文献

1
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).维奈托克与低甲基化药物（HMA）用于新诊断、复发或难治性KMT2A重排急性髓系白血病（AML）患者的临床经验
Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10.
2
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
3
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.阿瓦隆研究：关于低甲基化药物联合维奈克拉在新诊断或复发/难治性急性髓系白血病患者中的真实疗效的意大利队列研究。
Cancer. 2023 Apr 1;129(7):992-1004. doi: 10.1002/cncr.34608. Epub 2023 Jan 24.
4
The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.维奈托克联合低甲基化剂与 HAG 方案治疗急性髓系白血病患者的疗效：一项回顾性研究。
Hematology. 2024 Dec;29(1):2350319. doi: 10.1080/16078454.2024.2350319. Epub 2024 May 15.
5
Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.维奈托克联合低甲基化药物治疗初治 B/髓系混合表型急性白血病和复发/难治性急性髓系白血病：3 例报告。
Chemotherapy. 2022;67(3):178-182. doi: 10.1159/000519882. Epub 2022 Mar 18.
6
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.我们如何将维奈托克纳入急性髓系白血病的治疗方案中。
Cancer J. 2022;28(1):2-13. doi: 10.1097/PPO.0000000000000567.
7
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM. Venetoclax 单药治疗对低甲基化药物难治性继发性 AML 且高表达 BCL-2 和/或 BIM 患者具有持久缓解作用。
Eur J Haematol. 2019 May;102(5):437-441. doi: 10.1111/ejh.13218. Epub 2019 Feb 28.
8
Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.维奈托克和低甲基化药物在新诊断的急性髓系白血病患者中产生高缓解率和良好的移植结果。
Br J Haematol. 2022 Mar;196(6):e71-e74. doi: 10.1111/bjh.17996. Epub 2021 Dec 21.
9
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.初治急性髓系白血病中对维奈托克加去甲基化药物反应的分子预测指标
Haematologica. 2022 Oct 1;107(10):2501-2505. doi: 10.3324/haematol.2022.281214.
10
SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML.SOHO 最新进展及未来展望： Venetoclax 为基础的 AML 治疗的过去、现在和未来。
Clin Lymphoma Myeloma Leuk. 2021 Dec;21(12):805-811. doi: 10.1016/j.clml.2021.07.012. Epub 2021 Jul 18.

引用本文的文献

1
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements.新诊断的伴有KMT2A重排的急性髓系白血病的特征及预后
Leukemia. 2025 May 9. doi: 10.1038/s41375-025-02634-2.
2
Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition.鸟嘌呤核苷酸生物合成阻断会损害MLL复合物的形成，并使白血病对Menin抑制敏感。
Nat Commun. 2025 Mar 18;16(1):2641. doi: 10.1038/s41467-025-57544-9.
3
Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy.
维奈托克联合去甲基化药物治疗复发/难治性急性髓系白血病患者反应和生存的分子预测指标
Haematologica. 2025 Aug 1;110(8):1865-1869. doi: 10.3324/haematol.2024.286991. Epub 2025 Feb 27.
4
Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives.白血病中的重排：分子方面和治疗前景。
Int J Mol Sci. 2024 Aug 20;25(16):9023. doi: 10.3390/ijms25169023.
5
Mutations in Patients with Myeloid Neoplasms: A Cancer Center Multigene Next-Generation Sequencing Analysis Experience.骨髓增生性肿瘤患者的突变：癌症中心多基因下一代测序分析经验。
Int J Mol Sci. 2024 May 9;25(10):5183. doi: 10.3390/ijms25105183.
6
Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?维奈托克：高危髓系恶性肿瘤患儿治疗的新选择？
Blood Adv. 2024 Jul 9;8(13):3583-3595. doi: 10.1182/bloodadvances.2023012041.
7
Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements.两例伴有 KMT2A 重排的大细胞转化蕈样肉芽肿。
J Hematop. 2023 Dec;16(4):227-234. doi: 10.1007/s12308-023-00567-2. Epub 2023 Nov 23.
8
Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies. Venetoclax 联合疗法在儿科血液系统恶性肿瘤中的最新进展。
Int J Mol Sci. 2023 Nov 24;24(23):16708. doi: 10.3390/ijms242316708.